ClinicalTrials.gg
RecruitingNCT05187819Updated Sep 28, 2023

Blood-based Biomarkers for Diagnosis of Alzheimer's

An interventional study of predictive value of a blood test in Dementia Alzheimers, sponsored by Helse Stavanger HF. Recruiting at 1 site in Norway. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Helse Stavanger HF · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Alzheimer Disease with a site in Norway — 11 open to participants now, 15 under way, none of them phase 3. Alzheimer Disease · Norway.

Planned enrollment
11th of 37
300 · median 187
Started
2023
with 3 others
No phase
18 of 43
4 open now
Primary completion
2026-12
later than 5 of 14 live
Registered
30th of 43
by date
Lead sponsor
3 of 43
Helse Stavanger HF

Among the 43 studies in Alzheimer Disease with a site in Norway, this one is the 11th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2023, is one of 18 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 30th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

11 of the 43 studies in Alzheimer Disease with a site in Norway are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 40 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Alzheimer Disease with a site in Norway, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.

This project will assess the predictive value of these tests in a general practice population.

The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.

Read the detailed description

A correct diagnosis of dementia is important in order to provide the patient and relatives with right information, and to give adequate treatment and support, but also to improve research and further development of treatment. Alzheimer's disease (AD) is the cause of nearly 2/3 of cases of dementia. Current diagnostic methods to ensure accurate diagnosis include analysis of cerebrospinal fluid and molecular PET, but these methods are expensive and not widely available.

Progress has been made in the development of blood-based diagnostic biomarkers for Alzheimer's disease. It will lead to significant simplification and improvement of clinical practice if simple blood tests that can be taken in general practice can provide a reliable diagnosis of Alzheimer's disease.

Several biomarkers (including phosphorylated tau 181, phosphorylated tau 217, phosphorylated tau 231, plasma glial fibrillary acidic protein, plasma β-amyloid 42 to β-amyloid 40 ratio, and plasma neurofilament light) has documented to be useful to distinguish Alzheimer's dementia from non-Alzheimer's dementia in research cohorts with a high prevalence of AD. This project aims to analyze the diagnostic ability of such biomarkers in a primary care cohort with a lower prevalence of AD.

The Stavanger region in Norway will be the catchment area for recruitment of study participants. The region is geographically distinct with 373,000 inhabitants, 15 municipalities with 320 GPs in 94 clinics, all served by one hospital. Consequently, the region offers unique opportunities for community-wide implementation research.

All General Practitioners (GPs) in the region will be invited to, upon consent, select participants for the study. To reflect real-life medical practice in primary care, broad inclusion criteria have been chosen. Blood samples will be taken at the GP offices. First, the robustness of the samples regarding temperature, time and transportation to the laboratory will be studied. Second, the results of the blood samples will be compared with the results of standard diagnostic procedures at the memory outpatient clinic at the hospital. A random sample of an equal number of patients with positive and negative blood biomarker test-results will undergo blinded specialist examination, including MRIs of the brain and analysis of the cerebrospinal fluid for Alzheimer biomarkers. The diagnosis made by the specialists will then be compared to the blood-test results in order to estimate the positive and negative predictive value of such biomarkers for the diagnosis of AD in general practice.

03

Conditions studied

  • Dementia Alzheimers

Keywords

  • Alzheimer's dementia
  • Diagnosis
  • Biomarkers
  • Clinical practice
04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening

Exclusion criteria

Exclusion Criteria:

  • Lack of capacity for consent as judged by the GP.
  • Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.
  • Patients not wanting to be referred to the memory outpatient clinic.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Patients with positive blood test for biomarkers for Alzheimer's disease

    The positive blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false positive blood tests (using the results from the outpatient clinic as a "gold standard" for the diagnosis)

    Diagnostic Test: predictive value of a blood test

  • Active comparator
    Patients with negative blood test for biomarkers for Alzheimer's disease

    The negative blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false negative blood tests (using the results from the outpatient clinic as a "gold standard" for the diagnosis)

    Diagnostic Test: predictive value of a blood test

Interventions

  • Diagnostic testpredictive value of a blood test

    Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.

06

What researchers measure

Primary outcomes

  1. The positive predictive value

    The positive predictive value of the blood biomarkers for diagnosing Alzheimer's disease in general practice

    Time frame: 2 years

  2. The negative predictive value

    The positive predictive value of the blood biomarkers for diagnosing Alzheimer's disease in general practice

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 42 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2021
First posted
Jan 12, 2022
StartActual
Jun 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2029
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05187819
Lead sponsor
Helse Stavanger HF
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Jun 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 28, 2023

Study contacts

Svein R Kjosavik, MD PhD
Contact
svein.kjosavik@sus.no
+4790414252
Anita L. Sunde, MD
Contact
anita.lenora.sunde@sus.no
+4746696494
Svein Skeie, MD PhD
study director · Helse Stavanger HF

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion